F
Faisal A. Khokhar
Researcher at Regeneron
Publications - 34
Citations - 518
Faisal A. Khokhar is an academic researcher from Regeneron. The author has contributed to research in topics: Dupilumab & Medicine. The author has an hindex of 4, co-authored 11 publications receiving 142 citations.
Papers
More filters
Journal ArticleDOI
Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial
Amy S. Paller,Amy S. Paller,Elaine C. Siegfried,Elaine C. Siegfried,Diamant Thaçi,Andreas Wollenberg,Michael J. Cork,Peter D. Arkwright,Melinda Gooderham,Lisa A. Beck,Mark Boguniewicz,Lawrence Sher,Jamie Weisman,John T. O'Malley,Naimish Patel,Megan Hardin,Neil M.H. Graham,Marcella Ruddy,Xian Sun,John D. Davis,Mohamed A. Kamal,Faisal A. Khokhar,David M. Weinreich,George D. Yancopoulos,Bethany Beazley,Ashish Bansal,Brad Shumel +26 more
TL;DR: Dupilumab+TCS is efficacious and well tolerated in children with severe AD, significantly improving signs, symptoms, and QoL.
Journal ArticleDOI
Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS).
A. Wollenberg,Lisa A. Beck,Andrew Blauvelt,Eric L. Simpson,Zhen Chen,Q. Chen,Brad Shumel,Faisal A. Khokhar,Thomas Hultsch,E. Rizova,Ana B. Rossi,N.M.H. Graham,Gianluca Pirozzi,Yufang Lu,Marius Ardeleanu +14 more
TL;DR: Dupilumab [a monoclonal antibody blocking the shared receptor subunit for interleukin (IL)‐4 and IL‐13] is approved for patients aged ≥ 12 years with inadequately controlled, moderate‐to‐severe atopic dermatitis (AD).
Journal ArticleDOI
Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.
Lisa A. Beck,Diamant Thaçi,Mette Deleuran,Andrew Blauvelt,Robert Bissonnette,Marjolein S. de Bruin-Weller,Michihiro Hide,Lawrence Sher,Iftikhar Hussain,Zhen Chen,Faisal A. Khokhar,Bethany Beazley,Marcella Ruddy,Naimish Patel,Neil M.H. Graham,Marius Ardeleanu,Brad Shumel +16 more
TL;DR: These safety and efficacy results support dupilumab as a continuous long-term treatment for adults with moderate-to-severe atopic dermatitis.
Journal ArticleDOI
Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study
Michael E. Wechsler,Linda B. Ford,Jorge Maspero,Ian D. Pavord,Alberto Papi,Arnaud Bourdin,Henrik Watz,Mario Castro,Natalia M Nenasheva,Yuji Tohda,David Langton,Guido Cardona,Christian Domingo,Hae-Sim Park,Kenneth R. Chapman,Xuezhou Mao,Yi Zhang,Asif H. Khan,Yamo Deniz,Paul Rowe,Upender Kapoor,Faisal A. Khokhar,Leda Mannent,Marcella Ruddy,Elizabeth Laws,Nikhil Amin,Megan Hardin +26 more
TL;DR: The TRAVERSE trial as mentioned in this paper evaluated the long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma, as data for extended treatment beyond 1 year are not available.
Journal ArticleDOI
Effect of Dupilumab on Blood Eosinophil Counts in Patients With Asthma, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis, or Eosinophilic Esophagitis.
Michael E. Wechsler,Amy D. Klion,Pierluigi Paggiaro,Parameswaran Nair,Delphine Staumont-Sallé,Amr Radwan,Robert R. Johnson,Upender Kapoor,Faisal A. Khokhar,Nadia Daizadeh,Zheng Chen,Elizabeth Laws,Benjamin Ortiz,Juby A. Jacob-Nara,Leda Mannent,Paul Rowe,Yamo Deniz +16 more
TL;DR: Transient increases in blood eosinophil counts have been observed in dupilumab clinical trials as mentioned in this paper , but these increases did not affect efficacy and were rarely of clinical consequence.